# Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer

> **NCT03964337** · PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 3 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Cancer Adenocarcinoma
- Non-Metastatic

## Interventions

- **DRUG:** Cabozantinib
- **PROCEDURE:** Radical Prostatectomy

## Key facts

- **NCT ID:** NCT03964337
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-17
- **Primary completion:** 2021-06-04
- **Final completion:** 2021-06-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Poor accrual.
- **Last updated:** 2022-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03964337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03964337, "Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03964337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*